362 related articles for article (PubMed ID: 26137574)
1. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.
Jabbari A; Dai Z; Xing L; Cerise JE; Ramot Y; Berkun Y; Sanchez GA; Goldbach-Mansky R; Christiano AM; Clynes R; Zlotogorski A
EBioMedicine; 2015 Apr; 2(4):351-5. PubMed ID: 26137574
[TBL] [Abstract][Full Text] [Related]
2. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.
Xing L; Dai Z; Jabbari A; Cerise JE; Higgins CA; Gong W; de Jong A; Harel S; DeStefano GM; Rothman L; Singh P; Petukhova L; Mackay-Wiggan J; Christiano AM; Clynes R
Nat Med; 2014 Sep; 20(9):1043-9. PubMed ID: 25129481
[TBL] [Abstract][Full Text] [Related]
3. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.
King B; Shapiro J; Ohyama M; Egeberg A; Piraccini BM; Craiglow B; Sinclair R; Chen YF; Wu WS; Ding Y; Somani N; Dutronc Y
Br J Dermatol; 2023 Nov; 189(6):666-673. PubMed ID: 37708254
[TBL] [Abstract][Full Text] [Related]
4. A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System.
Song CJ; Riley CA; Wilkison BD; Cho S
Mil Med; 2024 Jun; ():. PubMed ID: 38850223
[TBL] [Abstract][Full Text] [Related]
5. Baricitinib for the treatment of alopecia areata in adults: Real-world analysis of 36 patients.
Moreno-Vílchez C; Bonfill-Ortí M; Bauer-Alonso A; Notario J; Figueras-Nart I
J Am Acad Dermatol; 2024 May; 90(5):1059-1061. PubMed ID: 38246562
[No Abstract] [Full Text] [Related]
6. Improvement of severe alopecia areata in an adolescent patient on upadacitinib.
Ha GU; Kim JH; Jang YH
Pediatr Dermatol; 2024; 41(2):356-358. PubMed ID: 38151479
[TBL] [Abstract][Full Text] [Related]
7. Effect of baricitinib in patients with alopecia areata: Usefulness of trichoscopic evaluation.
Diluvio L; Matteini E; Lambiase S; Cioni A; Gaeta Shumak R; Dattola A; Bianchi L; Campione E
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e478-e480. PubMed ID: 38084867
[No Abstract] [Full Text] [Related]
8. Subclinical, early hair regrowth in alopecia areata patients under treatment with baricitinib detected by line-field confocal optical coherence tomography evaluation.
Verzì AE; Lacarrubba F; Dall'Oglio F; Rini S; Tosti A; Micali G
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e459-e461. PubMed ID: 37909307
[No Abstract] [Full Text] [Related]
9. Crisp1 and alopecia areata in C3H/HeJ mice.
Sundberg JP; Awgulewitsch A; Pruett ND; Potter CS; Silva KA; Stearns TM; Sundberg BA; Muñoz MW; Cuasnicu PS; King LE; Rice RH
Exp Mol Pathol; 2014 Dec; 97(3):525-8. PubMed ID: 25446841
[TBL] [Abstract][Full Text] [Related]
10. Novel investigational drugs for alopecia areata and future perspectives.
Chim I; Ghiya R; Sinclair RD; Eisman S
Expert Opin Investig Drugs; 2024 May; 33(5):441-449. PubMed ID: 38682280
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of T-cell activity in alopecia areata: recent developments and new directions.
Passeron T; King B; Seneschal J; Steinhoff M; Jabbari A; Ohyama M; Tobin DJ; Randhawa S; Winkler A; Telliez JB; Martin D; Lejeune A
Front Immunol; 2023; 14():1243556. PubMed ID: 38022501
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta-analysis.
Husein-ElAhmed H; Husein-ElAhmed S
J Eur Acad Dermatol Venereol; 2024 May; 38(5):835-843. PubMed ID: 38279559
[TBL] [Abstract][Full Text] [Related]
13. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib.
Craiglow B; Lee YW; Vañó-Galván S; Egeberg A; Dutronc Y; Durand F; Pierce E; Yu G; Chen YF; Mostaghimi A
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38904749
[TBL] [Abstract][Full Text] [Related]
14. Exploring Janus kinase inhibitors for alopecia areata: a comprehensive review.
Bushwereb R; Srivastava G
Ital J Dermatol Venerol; 2024 May; ():. PubMed ID: 38780910
[TBL] [Abstract][Full Text] [Related]
15. Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment.
Caldarola G; Pinto LM; Bellinato F; Bernardini N; Campione E; Chiricozzi A; Colonna L; De Simone C; Diluvio L; Gisondi P; Matteini E; Tomassetti E; Tolino E; Bianchi L; Peris K
Expert Opin Drug Saf; 2024 May; ():1-5. PubMed ID: 38717372
[TBL] [Abstract][Full Text] [Related]
16. Blockade of IL-7 signaling suppresses inflammatory responses and reverses alopecia areata in C3H/HeJ mice.
Dai Z; Wang EHC; Petukhova L; Chang Y; Lee EY; Christiano AM
Sci Adv; 2021 Apr; 7(14):. PubMed ID: 33811067
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development.
Wojciechowski J; S Purohit V; Huh Y; Banfield C; Nicholas T
Clin Pharmacokinet; 2023 Dec; 62(12):1765-1779. PubMed ID: 37917289
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of alopecia areata-associated trachyonychia with baricitinib.
Rózsa P; Degovics D; Baltás E; Gyulai R; Kemény L
Int J Dermatol; 2024 Mar; ():. PubMed ID: 38514896
[No Abstract] [Full Text] [Related]
19. Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS.
Cetin Gedik K; Ortega-Villa AM; Materne G; Rastegar A; Montealegre Sanchez GA; Reinhardt A; Brogan PA; Berkun Y; Murias S; Robles M; Schalm S; de Jesus AA; Goldbach-Mansky R
Ann Rheum Dis; 2024 Apr; ():. PubMed ID: 38653530
[TBL] [Abstract][Full Text] [Related]
20. Response to Moreno-Vílchez et al., "Baricitinib for the treatment of alopecia areata in adults: Real world analysis of 36 patients".
Desai D; Nohria A; Shapiro J; Lo Sicco K
J Am Acad Dermatol; 2024 Apr; ():. PubMed ID: 38631444
[No Abstract] [Full Text] [Related]
[Next] [New Search]
